MACROGENICS, INC. (MGNX) Operating Margin
- Operating margin · 12 months: Value -21.73%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -21.73% | Operating income / revenue. Period ending 2026-06-30. $-38.06M ÷ $175.14M × 100 ≈ -21.73% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -38.06M USD | Operating Income (Loss) |
| Revenue | 175.14M USD | |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 140.44M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-38.06M | $175.14M | (m) | $140.44M | (m) | -21.73% |
| 2026-03-31 | $-63.66M | $157.08M | (m) | $142.45M | (m) | -40.52% |
| 2025-12-31 | $-72.84M | $149.50M | $0.00 | $147.17M | (m) | -48.72% |
| 2025-09-30 | $-113.58M | $127.63M | $233.00K | $152.09M | (m) | -89.00% |
| 2025-06-30 | $-78.03M | $165.50M | $401.00K | $159.92M | (m) | -47.15% |
| 2025-03-31 | $-99.45M | $154.05M | $577.00K | $170.86M | (m) | -64.56% |
| 2024-12-31 | $-110.58M | $149.96M | $847.00K | $177.19M | (m) | -73.74% |
| 2024-09-30 | $-107.09M | $141.33M | $777.00K | $185.66M | (m) | -75.78% |
| 2024-06-30 | $-196.79M | $41.02M | $694.00K | $175.24M | (m) | -479.76% |
| 2024-03-31 | $-183.57M | $43.36M | $776.00K | $166.74M | (m) | -423.39% |
| 2023-12-31 | $-168.24M | $58.75M | $619.00K | $166.58M | (m) | -286.38% |
| 2023-09-30 | $-106.91M | $121.13M | $572.00K | $164.89M | (m) | -88.26% |
| 2023-06-30 | $-96.36M | $152.47M | $3.49M | $182.94M | (m) | -63.20% |
| 2023-03-31 | $-93.21M | $165.34M | $3.42M | $191.46M | (m) | -56.37% |
| 2022-12-31 | $-121.42M | $151.94M | $3.35M | $207.03M | (m) | -79.91% |
| 2022-09-30 | $-191.64M | $92.99M | $4.18M | $217.23M | (m) | -206.09% |
| 2022-06-30 | $-219.67M | $66.92M | $2.84M | $218.86M | (m) | -328.27% |
| 2022-03-31 | $-218.14M | $71.67M | $2.68M | $222.89M | (m) | -304.38% |
| 2021-12-31 | $-202.79M | $77.45M | $2.65M | $214.58M | (m) | -261.85% |
| 2021-09-30 | $-146.73M | $115.99M | (m) | $201.02M | (m) | -126.50% |
| 2021-06-30 | $-129.88M | $118.58M | (m) | $195.86M | (m) | -109.53% |
| 2021-03-31 | $-136.91M | $108.08M | (m) | $197.43M | (m) | -126.67% |
| 2020-12-31 | $-131.06M | $104.88M | (m) | $193.20M | (m) | -124.96% |
| 2020-09-30 | $-167.54M | $77.38M | (m) | $202.86M | (m) | -216.51% |
| 2020-06-30 | $-169.35M | $77.87M | (m) | $203.05M | (m) | -217.48% |
| 2020-03-31 | $-175.01M | $68.21M | (m) | $197.14M | (m) | -256.59% |
| 2019-12-31 | $-177.19M | $64.19M | (m) | $195.31M | (m) | -276.04% |
| 2019-09-30 | $-180.21M | $54.79M | (m) | $190.28M | (m) | -328.91% |
| 2019-06-30 | $-177.27M | $56.85M | (m) | $191.64M | (m) | -311.83% |
| 2019-03-31 | $-168.61M | $65.09M | (m) | $192.22M | (m) | -259.05% |
| 2018-12-31 | $-171.21M | $60.12M | (m) | $190.83M | (m) | -284.77% |
| 2018-09-30 | $-24.56M | $196.69M | (m) | $182.89M | (m) | -12.49% |
| 2018-06-30 | $-37.28M | $177.55M | (m) | $177.65M | (m) | -21.00% |
| 2018-03-31 | $-34.15M | $160.38M | (m) | $160.10M | (m) | -21.29% |
| 2017-12-31 | $-22.14M | $157.74M | (m) | $147.23M | (m) | -14.04% |
| 2017-09-30 | $-162.35M | $10.49M | (m) | $139.35M | (m) | -1547.81% |
| 2017-06-30 | $-148.89M | $12.08M | (m) | $128.67M | (m) | -1232.44% |
| 2017-03-31 | $-67.62M | $91.09M | (m) | $127.55M | (m) | -74.23% |
| 2016-12-31 | $-60.04M | $91.88M | (m) | $122.09M | (m) | -65.35% |
| 2016-09-30 | $-53.38M | $94.95M | (m) | $121.03M | (m) | -56.22% |
| 2016-06-30 | $-34.56M | $106.38M | (m) | $114.83M | (m) | -32.49% |
| 2016-03-31 | $-95.95M | $32.42M | (m) | $104.15M | (m) | -295.94% |
| 2015-12-31 | $-20.18M | $100.85M | (m) | $98.27M | (m) | -20.01% |
| 2015-09-30 | $-10.62M | $98.15M | (m) | $87.88M | (m) | -10.82% |
| 2015-06-30 | $895.00K | $101.85M | (m) | $82.41M | (m) | 0.88% |
| 2015-03-31 | $9.93M | $104.36M | (m) | $77.08M | (m) | 9.51% |
| 2014-12-31 | $-38.31M | $47.80M | (m) | $70.19M | (m) | -80.16% |
| 2014-09-30 | $-22.50M | $57.23M | (m) | $64.88M | (m) | -39.32% |
| 2014-06-30 | $-11.42M | $59.08M | (m) | $57.34M | (m) | -19.32% |
| 2014-03-31 | $588.89K | $62.16M | (m) | $51.05M | (m) | 0.95% |
| 2013-12-31 | $365.98K | $58.03M | (m) | $46.58M | (m) | 0.63% |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $48.78M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $53.91M | (m) | (m) | (m) | (m) |
| 2012-12-31 | $8.21M | $63.83M | (m) | $45.43M | (m) | 12.86% |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $5.25M | $57.21M | (m) | $41.09M | (m) | 9.18% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |